{"id":9014,"date":"2025-03-19T11:27:35","date_gmt":"2025-03-19T16:27:35","guid":{"rendered":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/?p=9014"},"modified":"2025-03-19T11:27:38","modified_gmt":"2025-03-19T16:27:38","slug":"antiviral-drug-ensitrelvir-shows-promise-in-preventing-household-covid-spread","status":"publish","type":"post","link":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/2025\/03\/19\/antiviral-drug-ensitrelvir-shows-promise-in-preventing-household-covid-spread\/","title":{"rendered":"Antiviral drug ensitrelvir shows promise in preventing household COVID spread"},"content":{"rendered":"<div class=\"panel body-content\"><div class=\"panel__container\">\n<p><a href=\"https:\/\/www.cidrap.umn.edu\/covid-19\/antiviral-drug-ensitrelvir-shows-promise-preventing-household-covid-spread\">CIDRAP<\/a> People who started taking the antiviral drug ensitrelvir within 72 hours after a household member tested positive for COVID-19 were significantly less likely to be infected, according to results from an international phase 3 clinical&nbsp;<a href=\"https:\/\/www.eurekalert.org\/news-releases\/1076714\" target=\"_blank\" aria-label=\"trial, opens in a new window\" rel=\"noreferrer noopener\">trial<\/a>&nbsp;presented last week at the Conference on Retroviruses and Opportunistic Infections in San Francisco.<\/p>\n\n\n\n<p>Made by Japanese pharmaceutical firm Shionogi, ensitrelvir is approved in Japan for the treatment of mild to moderate COVID-19.&nbsp;<\/p>\n\n\n\n<p>Researchers conducted the double-blind Stopping&nbsp;COVID-19 pRogression with early&nbsp;Protease&nbsp;InhibitOr treatment\u2014Post-Exposure&nbsp;Prophylaxis (SCORPIO-PEP) trial evaluating a 5-day course of oral ensitrelvir for post-exposure infection prevention from June 2023 to September 2024. Among all participants, 37% had at least one risk factor for serious COVID-19 complications.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">67% risk reduction&nbsp;<\/h3>\n\n\n\n<p>Of the 2,387 trial participants aged 12 years and older in countries that included the United States, 9.0% of placebo recipients contracted COVID-19 from a household member, compared with 2.9% of ensitrelvir recipients, for a 67% reduction in the risk of symptomatic infection, and the two groups had a similar risk of adverse events.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.cidrap.umn.edu\/covid-19\/antiviral-drug-ensitrelvir-shows-promise-preventing-household-covid-spread\">Continue reading<\/a><\/p>\n<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>CIDRAP People who started taking the antiviral drug ensitrelvir within 72 hours after a household member tested positive for COVID-19 were significantly less likely to be infected, according to results from an international phase 3 clinical&nbsp;trial&nbsp;presented last week at the Conference on Retroviruses and Opportunistic Infections in San Francisco. Made by Japanese pharmaceutical firm Shionogi, [&hellip;]<\/p>\n","protected":false},"author":11,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[13],"tags":[],"class_list":["post-9014","post","type-post","status-publish","format-standard","hentry","category-clinical-considerations"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/9014","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/comments?post=9014"}],"version-history":[{"count":1,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/9014\/revisions"}],"predecessor-version":[{"id":9015,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/posts\/9014\/revisions\/9015"}],"wp:attachment":[{"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/media?parent=9014"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/categories?post=9014"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.unmc.edu\/healthsecurity\/transmission\/wp-json\/wp\/v2\/tags?post=9014"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}